Reports Summarize Bladder Cancer Study Results from Department of Urology (Effect of Sequential Gemcitabine and Epirubicin Therapy On High-risk Non-muscle Invasive Bladder Cancer Following Transurethral Bladder Tumour Resection).

A study conducted in Anhui, People's Republic of China, investigated the efficacy of sequential gemcitabine and epirubicin therapy on high-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor (TURBT). The study analyzed the records of 100 high-risk NMIBC patients who underwent TURBT at Tongling People's Hospital. The results showed that sequential therapy with gemcitabine and epirubicin was effective in treating high-risk NMIBC after TURBT, reducing postoperative recurrence rates and improving postoperative quality of life without increasing adverse reactions. However, further analysis is needed for improved outcomes. [Extracted from the article]